{"schema_version":"secwatch.filing_event.v1","accession":"0001601830-26-000112","form_type":"8-K","ticker":"RXRX","cik":"0001601830","company_name":"RECURSION PHARMACEUTICALS, INC.","filed_at":"2026-09-21T13:05:27+00:00","discovered_at":"2026-09-21T13:06:00.339423+00:00","generated_at":"2026-09-21T13:06:12.034224+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Recursion amends Tempus master agreement, grants RNA model license for $12M","bullets":["Amendment extends Master Agreement term to six years, eliminates termination-for-convenience clause.","Annual License Fees for years 3-5 revised to $14M each, with at least $4M cash, rest in stock/cash.","Recursion grants Tempus non-exclusive oncology-only license to TxFM RNA model for 2 years.","Tempus pays $12M total license fee in two $6M installments; first on execution, second at one-year.","Tempus provides Recursion access to de-identified pathology records with linked clinical data."],"urls":{"canonical":"https://secwatch.observer/filing/0001601830-26-000112","json":"https://secwatch.observer/filing/0001601830-26-000112.json","markdown":"https://secwatch.observer/filing/0001601830-26-000112.md","text":"https://secwatch.observer/filing/0001601830-26-000112.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601830/000160183026000112/0001601830-26-000112-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601830/000160183026000112/rxrx-20260915.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-21T13:06:12.034224+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}